Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 1
1967 1
1975 1
1977 2
1978 1
1979 1
1980 1
1981 1
1982 2
1983 6
1984 1
1985 1
1986 5
1987 6
1988 8
1989 11
1990 11
1991 21
1992 20
1993 21
1994 20
1995 31
1996 41
1997 38
1998 60
1999 77
2000 107
2001 104
2002 108
2003 129
2004 163
2005 188
2006 226
2007 284
2008 325
2009 366
2010 428
2011 496
2012 563
2013 586
2014 636
2015 702
2016 638
2017 717
2018 706
2019 719
2020 785
2021 838
2022 745
2023 761
2024 735
2025 770
2026 486

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12,189 results

Results by year

Filters applied: . Clear all
Page 1
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer.
Powles T, Kann AG, Castellano D, Gross-Goupil M, Nishiyama H, Bracarda S, Bjerggaard Jensen J, Makaroff L, Jiang S, Ku JH, Park SH, Reig Torras O, Ye D, Maruzzo M, Necchi A, Morales-Barrera R, Giunta EF, Lee JL, Tortora G, Ürün Y, Dolowy L, Erdem D, Pinto A, Grando F, Zou W, Assaf ZJ, Vuky J, Degaonkar V, Steinberg EE, Bellmunt J, Gschwend JE; IMvigor011 Investigators. Powles T, et al. Among authors: park sh. N Engl J Med. 2025 Dec 18;393(24):2395-2408. doi: 10.1056/NEJMoa2511885. Epub 2025 Oct 20. N Engl J Med. 2025. PMID: 41124204 Clinical Trial.
Anatomical vs Physiological Lesion Characteristics in Prediction of Acute Coronary Syndrome.
Yang S, Chung JW, Park SH, Zhang J, Lee K, Hwang D, Lee KS, Na SH, Doh JH, Nam CW, Kim TH, Shin ES, Chun EJ, Choi SY, Kim HK, Hong YJ, Park HJ, Kim SY, Husic M, Lambrechtsen J, Jensen JM, Nørgaard BL, Andreini D, Maurovich-Horvat P, Merkely B, Penicka M, de Bruyne B, Ihdayhid A, Ko B, Tzimas G, Leipsic J, Sanz J, Rabbat MG, Katchi F, Shah M, Tanaka N, Nakazato R, Asano T, Terashima M, Takashima H, Amano T, Sobue Y, Matsuo H, Otake H, Kubo T, Takahata M, Akasaka T, Kido T, Mochizuki T, Yokoi H, Okonogi T, Kawasaki T, Nakao K, Sakamoto T, Yonetsu T, Kakuta T, Yamauchi Y, Taylor CA, Bax JJ, Shaw LJ, Stone PH, Narula J, Koo BK. Yang S, et al. Among authors: park sh. JACC Cardiovasc Interv. 2025 Dec 8;18(23):2833-2845. doi: 10.1016/j.jcin.2025.09.006. JACC Cardiovasc Interv. 2025. PMID: 41371781
A spatially resolved human glioblastoma atlas reveals distinct cellular and molecular patterns of anatomical niches.
Sonpatki P, Park HJ, Xing YL, Han KY, Schroeder BA, Yu HJ, Kim HJ, Chowdhury T, Hwang JH, Nam SM, Byun YH, Kang H, Lee JH, Lee ST, Won JK, Kim TM, Choi SH, Ku JL, Lee S, Yun H, Park SH, Petritsch CK, Park CK, Park WY, Shah N. Sonpatki P, et al. Among authors: park sh. Nat Commun. 2026 Feb 20;17(1):2951. doi: 10.1038/s41467-026-69716-2. Nat Commun. 2026. PMID: 41714633 Free PMC article.
Pan-Asian subgroup analysis of EV-302/KEYNOTE-A39: a phase 3 study to evaluate enfortumab vedotin and pembrolizumab in patients with untreated advanced urothelial carcinoma.
Kikuchi E, Van der Heijden MS, Valderrama BP, Gupta S, Bedke J, Shin SJ, Li JR, Guo J, Danchaivijitr P, Kanesvaran R, Park SH, Su WP, Kandori S, Bae WK, Wong A, Gorla S, Bavle A, Yu X, Lu YT, Powles T. Kikuchi E, et al. Among authors: park sh. Int J Clin Oncol. 2026 Mar;31(3):436-446. doi: 10.1007/s10147-025-02950-8. Epub 2026 Jan 21. Int J Clin Oncol. 2026. PMID: 41563650 Free PMC article. Clinical Trial.
Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial.
Motzer RJ, McDermott R, Park SH, Burotto M, Iacovelli R, Verzoni E, Suárez C, Eto M, Cutuli HJ, Porta C, Kopp RM, Rottey S, Velasco G, Valderrama BP, Azad AA, Giorgi U, Pavic M, Tomczak P, Figlin R, Westgeest HM, Guida A, Necchi A, Schutz FA, Suelmann BBM, Haanen JBAG, Yuan SS, Perini RF, Wang D, Heng DYC, Schmidinger M; LITESPARK-011 Investigators. Motzer RJ, et al. Among authors: park sh. Lancet. 2026 Aug 29;408(10557):808-820. doi: 10.1016/S0140-6736(26)01089-5. Epub 2026 Aug 12. Lancet. 2026. PMID: 42586114 Clinical Trial.
Casdatifan shows durable response linked to HIF-2α biology in kidney cancer.
Choueiri TK, Merchán J, Patnaik A, Drakaki A, Rini BI, Rha SY, Lee JL, Ornstein MC, Kumar R, Hwang C, Shao Y, Park SH, Barata PC, McGregor BA, Foster P, Chen J, Eisen M, Cole H, Weeder B, Guan Y, Singh J, Kaplan A, Cho S, Markus R, Kabbarah O, McKay RR. Choueiri TK, et al. Among authors: park sh. Nature. 2026 Aug;656(8128):734-741. doi: 10.1038/s41586-026-10718-x. Epub 2026 Jul 1. Nature. 2026. PMID: 42386974 Free PMC article.
12,189 results
You have reached the last available page of results. Please see the User Guide for more information.